Clinical Activity of Alectinib in Advanced RET-Rearranged Non-Small Cell Lung Cancer.

Jessica J Lin,Elizabeth Kennedy,Lecia V Sequist,Priscilla K Brastianos,Kelly E Goodwin,Sara Stevens,Alexandra C Wanat, Lisa L Stober,Subba R Digumarthy,Jeffrey A Engelman,Alice T Shaw,Justin F Gainor

Journal of Thoracic Oncology（2016）

引用 83|浏览8

暂无评分

摘要

Alectinib demonstrated preliminary antitumor activity in patients with advanced RET-rearranged NSCLC, most of whom had received prior RET inhibitors. Larger prospective studies with longer follow-up are needed to assess the efficacy of alectinib in RET-rearranged NSCLC and other RET-driven malignancies. In parallel, development of more selective, potent RET TKIs is warranted.

查看译文

关键词

Alectinib,RET,Tyrosine kinase inhibitor,Lung cancer,NSCLC

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要